CBD: The Biotech Boom Investors Haven’t Woken Up To Yet
Remember the early days when legalization was first announced? THC biotech stocks were lightning hot, with investors desperate to find out where the next stock market boom was going to come from.
Now big pharmaceutical companies are moving in, the smaller companies are getting bought up, and smart investors are starting to look elsewhere for those high-growth, big-return stocks.
And that’s a smart call – because there’s a limit to how fast these companies can grow when the US government still hasn’t decided on the legal status of THC.
Savvy investors are starting to look elsewhere for high-growth biotech stocks in the same sector – and they’re discovering there’s a relatively untapped side to this market.
It all comes down to one simple chemical compound – THC. THC is psychoactive, which means it creates the ‘high’ feeling in users. That compound is why the plant is still classed a Schedule 1 federally prohibited substance in the US.
So you’re an investor who’s looking to capitalize on this upward trend in the biotech sector. You want rapid growth, without the uncertainty.
What’s the alternative?
Cannabidiol, more widely known as CBD.
CBD is a chemical compound known as a cannabinoid, meaning it comes from the same plant – but there’s one major difference.
It has no THC. CBD isn’t psychoactive, so there’s no ‘high’.
This means CBD products made from hemp plants are legal in all US states, Canada, much of Europe and Latin America.
That puts CBD stocks in a very strong position.
Because CBD products have a range of applications.
Athletes use CBD for pain relief and its anti-inflammatory properties.
Consumers use CBD in consumer cosmetics, beverages, and health supplements.
Doctors use CBD-based pharmaceuticals for treating epilepsy and Parkinson’s, and research is ongoing for other pharmaceutical uses.
These are all markets worth billions of dollars, and there’s demand for CBD products in them all – and that demand is growing.
The market for consumer CBD products is predicted to reach $2.1 billion USD by 2020.
There’s everything to play for with a fraction of the risk.
As an investment opportunity, CBD biotech stocks look strong. It’s just a matter of finding the right one.
So now you’re thinking: where can I find a stable biotech stock that delivers on all the potential growth CBD has to offer.
One small cap firm seems poised to make some serious gains:
Here’s why this stock has strong potential.
Performance is bullish – an increase of over 300%, which doesn’t seem to be slowing down.
Take a look:
So why the confidence?
Isodiol International Inc. (CSE: ISOL)(OTC: ISOLF) is actually profitable. Unaudited Q3 revenues for the period ending December 31, 2017 came to a substantial $5.89 million CDN for net operational profit of $202,254 CDN.
The company has been around for 7 years, providing raw phytoceutical ingredients to pharmaceutical companies.
Isodiol International Inc.’s (CSE: ISOL)(OTC: ISOLF) proprietary hemp oil, ISO99TM, is used in pharmaceutical and consumer products – it’s the foundation of a proven, profitable business model.
This isn’t a short-term surge. This is a solid pattern of sustained performance. Investors who got in early have already seen a surge in the value of their investment.
If you invested in Isodiol International Inc. (CSE: ISOL)(OTC: ISOLF) as recently as June 2017, when it was trading at $0.14 CDN a share, your investment would have increased by nearly 900% in less than a year.
GW Pharmaceuticals plc (Nasdaq:GWPH)
GW Pharmaceuticals is a British biotech company that’s experienced exponential growth in the last few years.
Shares of GWPH have rocketed from $8.90 USD a share during their 2013 IPO to a staggering $121 USD as of March 13, 2018.
That’s an increase of over 1200% in less than 5 years.
And their core product? A cannabinoid pharmaceutical.
That’s right – GW Pharmaceuticals created the world’s first cannabinoid pharmaceutical to receive widespread (excluding the United States) international approval.
It’s called Sativex, a pharmaceutical used to treat neuropathic pain in multiple sclerosis patients.
Starting to sound familiar? It should.
The company is backed by an executive team who have a solid track record as figures within the CBD and biotech industry, as well as firmly established entrepreneurs.
Chairman Of The Board Director
The Chairman, Aman Parmar, is both a veteran of the pharmaceutical industry and an established entrepreneur. He spent time as the Director of Canadian company Vanc Pharmaceuticals, and is currently also involved in Green Tech firm Canadian Zeolite.
Chief Executive Officer Director
Their CEO, Marcos Agramont, is a veteran of international hemp brands. Previous to Isodiol, he was the CEO of another CBD business – EVR Premium Hemp Oil.
He also worked alongside Isodiol International Inc. (CSE: ISOL)(OTC: ISOLF) President Troy Nihart at HempMeds PX.
Chief Financial Officer Director
The CFO, Bryan Loree, has been working in the industry for over 7 years. In addition to his responsibilities at Isodiol International Inc.(CSE: ISOL)(OTC: ISOLF), Loree is the CFO of a tech rm – Cannabix Technologies Inc – which is developing tools for work and law enforcement to detect traces of THC on breath.
Their President, Troy Nihart, is a serial entrepreneur. He’s accumulated over 20 years of business development, sales and public company experience. He’s also been instrumental in the development of the CBD industry and developing some of its most recognizable brands, most notably HempMeds – another distributor of CBD oil products. Mr. Nihart is also the founder of Kannaway, a distributor of CBD oil products.
Vice President, ISOBEV
Daniel Zuckerman, their Vice President of US Sales, has worked in the industry for over four years. Previous to Isodiol International Inc.(CSE: ISOL)(OTC: ISOLF), he was the Director of Military Sales for Monster Energy – responsible for managing over 1 million cases per year in energy drink sales.
Vice President, Canada Director
Soheil Samimi has spent years in the CBD space – in addition to his position at Isodiol International Inc.(CSE: ISOL)(OTC: ISOLF), Mr. Samimi is also the CEO of MediGreen, a Canadian company specializing in the distribution of CBD products across Canada.
But there’s also the value that broader experience brings – like Mr. Zuckerman’s time at Monster Energy.
To put things in perspective, Monster reported net sales of $810.4 million USD in 2017 Q4. The business is an astronomical success, by any standards.
This team has been busy acquiring the competition – Isodiol International Inc. (CSE: ISOL)(OTC: ISOLF) is currently completing the acquisition of Biosynthesis Pharma Group (BSPG) for $12,500,000 USD. BSPG produces a high-purity, bioactive CBD at 99.5+% purity for pharmaceutical applications.
And this is just the latest in a series of aggressive global acquisitions.
Their mission? ‘Be the global leader in CBD research, science, innovation and technology.’
Other recent acquisitions also include BSPG Laboratories Limited (BSPGL-UK), Purodiol Do Brasil Ltda (PUR-Brazil), Trigal Pharma GmbH (TP-Austria).
Acquiring these companies unlocks markets in the United Kingdom, Europe, Asia, South America and Central America. See the pattern?
This is a strategy of long-term global growth in pharmaceuticals.
And it’s working.
Research is currently ongoing to discover CBD’s medical potential. Currently, the greatest medical potential for CBD appears to be in pain relief – as both an anti-inflammatory and a painkiller.
Any smart investor knows that once a company starts to get medical approval for one of their products, the potential is huge. Just look at GW Pharmaceuticals.
The World Anti-Doping Agency (which works hand-in-hand with the US Anti-Doping Agency) removed hemp-derived CBD from their List of Prohibited Substances and Methods as of February 2018.
Getting approval from the World Anti-Doping Agency, for any product, is huge.
It’s a breakthrough – it means that CBD products are receiving international acceptance, leaving behind their THC-based counterparts.
But there’s another unexpected bonus: a whole new pool of brand ambassadors.
Introducing this man:
A former NFL champion, he suffered from chronic traumatic encephalopathy, or CTE, a condition that affects many NFL players. And he’s an outspoken supporter of Isodiol International Inc.’s (CSE: ISOL)(OTC: ISOLF) CBD products.
Washington used CBD products to help treat his CTE, and since then he’s become their highest profile brand advocate.
He gave Isodiol International Inc. (CSE: ISOL)(OTC: ISOLF) a huge platform – the 2018 Super Bowl LII in Minneapolis.
Washington was a huge presence at the Super Bowl, using his platform to discuss CTE, the benefits of CBD, and the potential of Isodiol International Inc.’s (CSE: ISOL)(OTC: ISOLF) products for treatment – particularly as an alternative to the easily abused and readily available opioids:
“There is a natural alternative that can cure the CTE issue the NFL is having. The government has a patent that says CBD acts as an antioxidant and neuroprotectant for the brain in relation to concussions. CBD is a great alternative to opioids and pharmaceuticals that players have been poisoned with. THE NFLPA has been very receptive and we are making traction.”
– Marvin Washington, Interview with Power 96.5 WNY
Why? Because there’s an appetite for change within the NFL, inside and out.
CTE has become a hot issue.
The public are horrified to discover the long-term effects of repeated brain trauma on NFL players.
The athletes want protection and treatment – treatment that doesn’t rely on easily abused opioids.
Washington offers a solution. He has a foot in both camps – he’s rallying public support for the cause to protect players, but as an advocate for CBD he’s giving the company’s products a global platform.
The viewing numbers for this year’s Super Bowl was a staggering 103.4 million viewers.
Now imagine CBD products become the therapeutic product of choice for the NFL. The potential is incredible.
In every high-growth sector, the company owns consumer products and brands:
The company is working hard to develop new products, or acquiring strong competitors offering CBD products in high demand.
The brand has a clear strategy:
Build international recognition with high-profile sponsorships in the sport and fitness world.
The brand was a key sponsor of the Arnold Sports Festival in Columbus, Ohio – the bodybuilding event founded by
Arnold Schwarzenegger – which is expected to attract over 200,000 attendees.
The brand is recruiting high-profile brand ambassadors with huge audiences – like Extreme Runner David Clark, who has over 10k Twitter followers.
But even more exciting is ISO-Sport’s movement into the European MMA scene.
ISO-Sport is a major sponsor of Cage Warriors, Europe’s leading Mixed Martial Arts (MMA) promotion.
These fights are watched internationally Europe and on the UFC’s streaming service, UFC Fight Pass .
To drive that partnership further, the brand has also partnered with two internationally recognised MMA fighters.
Chris Fishgold, English CWFC Lightweight champion – with over 9k Instagram followers.
Molly McCann, English CWFC World Title Contender – also with over 9k Instagram followers.
Shortly after, a distribution agreement was established with Nutritional High to distribute their infused drinks in Oregon, Washington, Illinois and Colorado.
The company also acquired Culinary Coffee Roasters LLC, a roaster and purveyor of coffee, tea, and blended formulations in Florida to help them launch and roast their specialty blends.
Why is all this so exciting? Because the Canadian government has legalized cannabinoid infused beverages. And that legitimacy means growth can take off.
Greater legalization is likely to create an explosive demand for CBD-infused beverages.
This is great news for the company. Why?
Because the organic functional food and beverage market is valued at over $400 billion USD.
The potential for growth in this market alone is astronomical.
Just look at another market that’s set for massive growth – Vaping.
It acquires Bradley’s Bioscience, an established manufacturer of hemp oil and nicotine e-liquids operating in the United States and the United Kingdom.
The global e-cigarette and vaporizer market is poised to reach approximately $61.4 billion USD by 2025.
This is another market that’s seeing powerful growth.
And what’s a large driving force behind that growth?
Cannabinoid vaping, including CBD products.
BeTru Organics provide consumers with pain relief cream and dietary supplements. Their core product oering is centred around CanaTru, a proprietary hemp extract.
And in skincare, there’s CannaCeuticals. Isodiol International Inc.’s (CSE: ISOL)(OTC: ISOLF) offering in the luxury skincare market – a market that’s anticipated to reach $147 billion USD in sales by 2020.
Isodiol International Inc is strategically positioned in several major growth verticals within a $1 Trillion USD Global Health and Wellness market.
Stock performance is strong.
But at 1.50 a share, this stock is still within reach.
Investors who act now can potentially still reap the rewards of this high-growth biotech company.
As of Q3 2017, the company is reporting unaudited Q3 revenues of $5.89 million CDN – a net operational profit of $202,254 CDN.
That’s a 16% increase on Q2 alone – this upward trend only looks set to continue.
That makes it a potentially viable long-term investment.
Global growth in pharmaceuticals.
Combine the fact that the World Anti Doping Agency relaxing its stance on CBD products.
A heavyweight executive team with experience in the CBD industry and beyond.
The team combines years of experience with successful CBD brands, including a President of Sales who’s been responsible for moving 1 million cases of Monster energy drink per year.
Brand ambassadors with international presence.
Marvin Washington is giving the company a platform that money can’t buy through the NFL – there’s widespread public outrage against CTE and the opiates used to treat the disease.
Imagine what happens to Isodiol’s stock if the NFL chooses to abandon opiates, and embrace CBD products as their choice of treatment for CTE.
A diverse portfolio of consumer brands in high-growth markets.
Each of these markets are expected to see billions of dollars in growth.
Isodiol’s success isn’t a matter of if – it’s a matter of when.
The biggest question is how much time investors have before this one gets discovered.
Because once the market tires of the uncertainty attached to THC, you can bet every smart investor is going to be looking to CBD, and Isodiol International Inc.(CSE: ISOL)(OTC: ISOLF), for a solution.
Important Notice and Disclaimer:
The BiotechStockNews.com website (“BiotechStockNews.com”) is owned and operated by Invictus Digital Marketing Group Inc. (“Invictus Digital Marketing”). ”, “we”, “us”, “our”). This page contains the terms and conditions that apply to your use of BiotechStockNews.com (the “Terms”). By using BiotechStockNews.com, you are agreeing to be legally bound by the Terms. If you do not agree to any Terms, you should not use BiotechStockNews.com.
Invictus Digital Marketing, its editors, affiliates, associates, partners, family members, or contractors may have an interest or position in featured, written-up companies, as well as sponsored companies which compensate Invictus Digital Marketing. Advertisers placing advertorials on BiotechStockNews.com pay Invictus Digital Marketing between Cdn$75,000 to Cdn$150,000 for a total production budget for these advertising efforts. Isodiol International Inc. (formerly Laguna Blends Inc.) (the “Company”) has paid Invictus Digital Marketing Cdn$150,000 for a period of three months for advertising and marketing services rendered on behalf of the Company. Other than as set forth above, neither Invictus Digital Marketing nor any of its directors or officers has any other financial or other interest in the Company. In addition, neither Invictus Digital Marketing nor any of its directors or officers beneficially owns any securities of the Company. read more